(Total Views: 364)
Posted On: 02/01/2020 4:34:35 PM
Post# of 154900
Re: I_luv_cydy #16586
I agree that it was confusing, but I think they would have included "and fourth Patient" in the headline if they were including both patients:
"Third patient data supports leronlimab (PRO 140) as a potential treatment option for metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Patient CTC dropped to zero after 2 weeks of leronlimab treatment, same as the first patient on leronlimab"
I'm not sure who's fault it was. I don't think the BoD proofs reads their PRs, but they need to be more careful going forward.
"Third patient data supports leronlimab (PRO 140) as a potential treatment option for metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Patient CTC dropped to zero after 2 weeks of leronlimab treatment, same as the first patient on leronlimab"
I'm not sure who's fault it was. I don't think the BoD proofs reads their PRs, but they need to be more careful going forward.
(0)
(0)
My comments are just my opinions and should NOT be taken as investment advice.
